Biao Yang1, Bo Zheng2, MaoNan Yang3, Zhu Zeng4, FangYun Yang4, Ji Pu2, ChunLin Li4, ZhengYin Liao5. 1. Department of Abdominal Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, 37 Guoxue Xiang, Chengdu, 610041, Sichuan, People's Republic of China. landayb@163.com. 2. Department of Interventional Radiology, High-Tech Hospital, Zigong, People's Republic of China. 3. Department of Oncology, LeShan Tradition Medicine Hospital, Leshan, People's Republic of China. 4. Department of Abdominal Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, 37 Guoxue Xiang, Chengdu, 610041, Sichuan, People's Republic of China. 5. Department of Abdominal Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, 37 Guoxue Xiang, Chengdu, 610041, Sichuan, People's Republic of China. liaozhengyin@163.com.
Abstract
AIMS: Current evidence supporting the efficacy of transarterial chemoembolization (TACE) in Barcelona Clinic Liver Cancer (BCLC)-B hepatocellular carcinoma (HCC) is controversial. The aim of this systematic review was to compare the benefits of liver resection (LR) versus TACE in BCLC-B HCC. METHODS: We conducted a comprehensive literature review of the EMBASE, PubMed, Google Scholar, and Chinese Biomedical Literature databases for retrospective or prospective studies evaluating the efficacy of LR and TACE for the treatment of BCLC-B HCC. RESULTS: Eleven studies incorporating 3366 patients were included in this analysis. 1-year (RR 0.52 95% CI 0.43-0.63, p < 0.001; I2 = 59%, p = 0.006), 3-year (RR 0.63 95% CI 0.59-0.67, p < 0.001; I2 = 16%, p = 0.29), and 5-year (RR 0.69 95% CI 0.63-0.75, p < 0.001; I2 = 56%, p = 0.021) OS were significantly improved in BCLC-B HCC patients that underwent LR compared to those that underwent TACE. Child-Pugh A liver disease (B vs. A) (HR 1.45 95% CI 1.17-1.79, p < 0.001; I2 = 0%, p = 0.49) and AFP levels (> 400 vs. ≤ 400 ng/ml) (HR 1.36 95% CI 1.09-1.71, p = 0.007; I2 = 90%, p = 0.001) were associated with improved OS. CONCLUSION: Liver resection had significant survival benefits over TACE in selected BCLC-B HCC patients in comparison to TACE. However, LR was associated with a significantly increased incidence of treatment-related mortality and infection compared to TACE.
AIMS: Current evidence supporting the efficacy of transarterial chemoembolization (TACE) in Barcelona Clinic Liver Cancer (BCLC)-B hepatocellular carcinoma (HCC) is controversial. The aim of this systematic review was to compare the benefits of liver resection (LR) versus TACE in BCLC-B HCC. METHODS: We conducted a comprehensive literature review of the EMBASE, PubMed, Google Scholar, and Chinese Biomedical Literature databases for retrospective or prospective studies evaluating the efficacy of LR and TACE for the treatment of BCLC-B HCC. RESULTS: Eleven studies incorporating 3366 patients were included in this analysis. 1-year (RR 0.52 95% CI 0.43-0.63, p < 0.001; I2 = 59%, p = 0.006), 3-year (RR 0.63 95% CI 0.59-0.67, p < 0.001; I2 = 16%, p = 0.29), and 5-year (RR 0.69 95% CI 0.63-0.75, p < 0.001; I2 = 56%, p = 0.021) OS were significantly improved in BCLC-B HCC patients that underwent LR compared to those that underwent TACE. Child-Pugh A liver disease (B vs. A) (HR 1.45 95% CI 1.17-1.79, p < 0.001; I2 = 0%, p = 0.49) and AFP levels (> 400 vs. ≤ 400 ng/ml) (HR 1.36 95% CI 1.09-1.71, p = 0.007; I2 = 90%, p = 0.001) were associated with improved OS. CONCLUSION: Liver resection had significant survival benefits over TACE in selected BCLC-B HCC patients in comparison to TACE. However, LR was associated with a significantly increased incidence of treatment-related mortality and infection compared to TACE.
Authors: Myeong Jun Song; Ho Jong Chun; Do Seon Song; Hee Yeon Kim; Sun Hong Yoo; Chung-Hwa Park; Si Hyun Bae; Jong Young Choi; U Im Chang; Jin Mo Yang; Hae Giu Lee; Seung Kew Yoon Journal: J Hepatol Date: 2012-07-20 Impact factor: 25.083
Authors: R Ciria; P López-Cillero; A-B Gallardo; J Cabrera; M Pleguezuelo; M-D Ayllón; A Luque; L Zurera; J-J Espejo; M Rodríguez-Perálvarez; J-L Montero; M de la Mata; J Briceño Journal: Eur J Surg Oncol Date: 2015-06-12 Impact factor: 4.424
Authors: Lei Jianyong; Yan Lunan; Wang Wentao; Zeng Yong; Li Bo; Wen Tianfu; Xu Minqing; Yang Jiaying Journal: Medicine (Baltimore) Date: 2014-11 Impact factor: 1.889